(Q40507477)

21 September 2017

Erythropoietin and erythropoietin receptor expression in human prostate cancer (English)

1 reference

21 September 2017

1 reference

Wendy Demark-Wahnefried

5

object named as

Wendy Demark-Wahnefried

1 reference

21 September 2017

Murat O Arcasoy

1

1 reference

21 September 2017

Khalid Amin

2

1 reference

21 September 2017

Robin T Vollmer

3

1 reference

21 September 2017

Xiaohong Jiang

4

1 reference

21 September 2017

Zishan A Haroon

6

1 reference

21 September 2017

1 March 2005

1 reference

21 September 2017

1 reference

21 September 2017

18

1 reference

21 September 2017

3

1 reference

21 September 2017

421-430

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.3800288

21 September 2017

0 references

cites work

Expression cloning of the murine erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin receptor mRNA expression in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Localization of specific erythropoietin binding sites in defined areas of the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

In vivo evidence that erythropoietin protects neurons from ischemic damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Estrogen-dependent production of erythropoietin in uterus and its implication in uterine angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

A novel role for erythropoietin during fibrin-induced wound-healing response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Immunohistochemical expression of erythropoietin and erythropoietin receptor in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Expression of erythropoietin receptor splice variants in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer--a randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: final report of a randomized, open-labelled, phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin in urologic oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Structural design and molecular evolution of a cytokine receptor superfamily

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

21 January 2018

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

A new hematopoietic growth factor receptor superfamily: structural features and implications for signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Production and response of human prostate cancer cell lines to granulocyte macrophage-colony stimulating factor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin receptor expression in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Inhibition of erythropoietin signalling destroys xenografts of ovarian and uterine cancers in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Erythropoietin regulates tumour growth of human malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Pediatric Tumor Cells Express Erythropoietin and a Functional Erythropoietin Receptor that Promotes Angiogenesis and Tumor Cell Survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

Guidelines for the use of epoetin in cancer patients: a much-needed step forward in standardizing anemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Erythropoietin receptor activation by a ligand-induced conformation change

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Functional significance of erythropoietin receptor expression in breast cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Expression of the erythropoietin receptor by trophoblast cellsin the human placenta

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Development of anemia and recovery in prostate cancer patients treated with combined androgen blockade and radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Anemia associated with advanced prostatic adenocarcinoma: effects of recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Erythropoietin stimulates proliferation of human renal carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Erythropoietin and G-CSF receptors in human tumor cells: expression and aspects regarding functionality.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Erythropoietin as an angiogenic factor in gastric carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Recombinant human erythropoietin in the treatment of the anaemia of cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Breast cancer trial with erythropoietin terminated unexpectedly

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800288

7 January 2021

10.1038/MODPATHOL.3800288

Identifiers

DOI

1 reference

Dimensions Publication ID

21 September 2017

0 references

1 reference